Innovative therapeutics

RSS Feed

Investors

Press Releases

Email Alerts

Nov 21, 2019

BioMarin Submits Marketing Authorization Application to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A

1st Marketing Application Submission for Gene Therapy Directed at Any Type of Hemophilia

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational...
Nov 14, 2019

Poised for Significant Growth and Profitability, BioMarin Shares Company Highlights During R&D Day on November 14th in New York

Valoctocogene Roxaparvovec on Track for US and EU Regulatory Submissions by Year End

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) updated the investment community on the Company's research and development portfolio, which is focused on innovative therapies to treat rare diseases....
Nov 14, 2019

BioMarin Announces Cumulative Additional Height Gain of 9.0 cm over 54 months versus Natural History in Children with Achondroplasia Treated with Vosoritide in Phase 2 Study

Company Plans to Provide Topline Phase 3 Data by Year End

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) provided an update on its clinical program for vosoritide, an analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia, the most...
Nov 12, 2019

BioMarin to Participate in Jefferies London Healthcare Conference on November 21, 2019

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Jefferies London Healthcare Conference on...
Nov 6, 2019

BioMarin to Highlight Innovative Development Pipeline at R&D Day on November 14th

- Key research & development pipeline products and data to be presented, including 54-month Phase 2 vosoritide data update for the treatment of achondroplasia -

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host an R&D Day at 8:00am ET on Thursday, November 14, 2019. BioMarin management and external experts will provide an update to the investment...
Oct 23, 2019

BioMarin Announces Third Quarter 2019 Financial Results

- The Company Achieved Record Total Revenues of $461.1 million; Increased 18% Year Over Year

Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 % Change 2019 2018 % Change Total...
Oct 9, 2019

BioMarin to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, October 23 at 4:30pm ET

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...
Oct 7, 2019
BioMarin Promotes Lon Cardon, Ph.D. to Chief Scientific Strategy Officer

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the promotion of Lon Cardon, Ph.D. to Chief Scientific Strategy Officer, a newly created role to enrich BioMarin's pipeline, which drives...
- Photos 1
Oct 1, 2019

BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Robert Baffi, Ph.D., President of Global Manufacturing and Technical Operations, will participate in a fireside discussion at the...
Sep 26, 2019

BioMarin, Pioneer in Phenylketonuria (PKU) Therapies, Submits Clinical Trial Application (CTA) in U.K. for Investigational Gene Therapy for PKU

BMN 307 Represents a Potential 3rd PKU Treatment Option in BioMarin's PKU Franchise

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a pioneer in treatments for rare disease Phenylketonuria (PKU) and in gene therapies, today announced that it has submitted a Clinical Trial Application...